The US is pushing ahead with plans for the next USD200bn tariff tranche by releasing the list of targeted products, which after public consultations could take effect as soon as end-August, notes the research team at Rabobank.
“Covered are low-tech goods such as clothing, TV components, refrigerators, and even foods, detailed chemicals like ”4,4'-Isopropylidenediphenol (Bisphenol A, Diphenylolpropane) and its salts”, as well as high-tech items squarely aimed at slowing China’s march to ‘2025’ industrial supremacy.”
“If we see these duties kick in, nearly half of all Chinese exports will be under tariffs.”
“China has immediately responded that it will “fight fire with fire” – and yet it can’t put USD200bn of tariffs in place as it doesn’t buy USD200bn more of US goods! So where do we go? Somewhere that says ‘risk on’? Note that at time of writing CNH was back at 6.69 again, and Chinese equities are tanking.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.